Malignant neoplasm of ovary
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Folate receptor alpha (αFR) is overexpressed in 90% of ovarian cancers, one of the most lethal gynecologic cancers.
|
31261167 |
2019 |
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
New tumor markers, such as PRSS8, FOLR1, KLK6/7, GSTT1, and miRNAs, are getting ahead and are worth noting for early detection of ovarian cancer.
|
31081307 |
2019 |
Malignant neoplasm of ovary
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In >80% of ovarian cancers, Folate Receptor-α (FR-α) is expressed at 10- to 100-fold higher levels than on non-pathological tissues.
|
29737910 |
2018 |
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
A Single-Agent Dual-Specificity Targeting of FOLR1 and DR5 as an Effective Strategy for Ovarian Cancer.
|
30107179 |
2018 |
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
Folate Receptor Alpha Expression in Platinum Resistant/Refractory Ovarian Carcinomas and Primary Endocervical Adenocarcinomas.
|
27941566 |
2018 |
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
FOLR1 may be a useful biomarker for ovarian cancer, and it may be useful as a therapeutic application to improve sensitivity to cisplatin treatment.
|
29433550 |
2018 |
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our previous identification of degenerate HLA-class II epitopes from human FR led to the development of a broad coverage epitope pool potentially useful in augmenting antigen-specific immune responses in most patients.<b>Patients and Methods:</b> We conducted a phase I clinical trial testing safety and immunogenicity of this vaccine, enrolling patients with ovarian cancer or breast cancer who completed conventional treatment and who showed no evidence of disease.
|
29545464 |
2018 |
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the present study, we modified CIK cells with FRα-specific CARs and investigated their antitumor immunity against ovarian cancers.
|
28360017 |
2017 |
Malignant neoplasm of ovary
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Folate binding protein(FBP) is an immunogenic protein over-expressed in endometrial(EC) and ovarian cancer(OC).
|
27852036 |
2017 |
Malignant neoplasm of ovary
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Therefore, FRα-targeted lipoplexes with therapeutic gene expression regulated by an hTERT promoter might be a promising gene therapy agent and a potential translational candidate for the clinical treatment of ovarian cancer.
|
27026065 |
2016 |
Malignant neoplasm of ovary
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
FOLR1 mRNA expression did not prove to predict clinical outcome in type II cancers, although strong FOLR1 expression generally denotes ovarian cancers with highly aggressive phenotype.
|
27485273 |
2016 |
Malignant neoplasm of ovary
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The objective of this study was to measure the levels of FOLR1 and Dkk-3 in the serum of patients with ovarian cancer, benign gynecological conditions and healthy women.
|
23528302 |
2013 |
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
Folate receptor alpha (FRalpha) is overexpressed on ovarian cancer cells and is a promising molecular target for ovarian cancer gene therapy, but there was still no related report.
|
23802413 |
2013 |
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study investigated the roles of folate, FRα and RFC in ovarian cancers.
|
23144806 |
2012 |
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
The chimeric antibody, MOv18 IgE, against the human ovarian carcinoma antigen, folate receptor α (FRα), is more effective than its IgG1 counterpart in xenograft models of ovarian cancer.
|
21569129 |
2011 |
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
Expression of the folate receptor genes FOLR1 and FOLR3 differentiates ovarian carcinoma from breast carcinoma and malignant mesothelioma in serous effusions.
|
19454358 |
2009 |
Malignant neoplasm of ovary
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Vaccination with dendritic cells transfected with mRNA-encoded folate-receptor-alpha for relapsed metastatic ovarian cancer.
|
17466904 |
2007 |
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
Together, the data suggest the possible predictive value of FBP in ovarian carcinoma, as higher levels of expression can be indirectly but significantly associated with increased drug sensitivity.
|
9218736 |
1997 |
Malignant neoplasm of ovary
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of folate binding protein in ovarian cancers.
|
9133455 |
1997 |
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
This molecule is a high affinity folate binding protein (FBP) and a potential marker for ovarian carcinoma.
|
8242637 |
1993 |
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
Folate-binding protein is a marker for ovarian cancer.
|
1717147 |
1991 |